Preclinical Animal Studies of Intravesical Recombinant Human Proteoglycan 4 as a Novel Potential Therapy for Diseases Resulting From Increased Bladder Permeability

• Published in: Urology (Ridgewood, N.J.) N.J.), 2018-06, Vol.116, p.230.e1-230.e7
• Main Authors: Greenwood-Van Meerveld, Beverley, Mohammadi, Ehsan, Latorre, Rocco, Truitt, Edward R., Jay, Gregory D., Sullivan, Benjamin D., Schmidt, Tannin A., Smith, Nataliya, Saunders, Debra, Ziegler, Jadith, Lerner, Megan, Hurst, Robert, Towner, Rheal A.
• Format: Article
• Language: English
• Subjects: Administration, Intravesical; Animals; Colon - diagnostic imaging; Colon - drug effects; Colon - metabolism; Colon - pathology; Cystitis, Interstitial - drug therapy; Cystitis, Interstitial - etiology; Cystitis, Interstitial - pathology; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Irritable Bowel Syndrome - drug therapy; Irritable Bowel Syndrome - etiology; Irritable Bowel Syndrome - pathology; Magnetic Resonance Imaging; Permeability - drug effects; Proteoglycans - pharmacology; Proteoglycans - therapeutic use; Rats; Rats, Sprague-Dawley; Recombinant Proteins - pharmacology; Recombinant Proteins - therapeutic use; Urinary Bladder - diagnostic imaging; Urinary Bladder - drug effects; Urinary Bladder - metabolism; Urinary Bladder - pathology
• ISSN: 0090-4295; 1527-9995
• DOI: 10.1016/j.urology.2018.02.034

To test in an animal model the hypothesis that recombinant human proteoglycan 4 (rhPRG4; lubricin), a highly O-glycosylated mucin-like glycoprotein, may be a novel surface-active therapeutic for treating bladder permeability with comorbid bowel permeability. Previously we showed that inducing bladder permeability in rats with dilute protamine sulfate (PS) produced colonic permeability and visceral hypersensitivity, suggesting increased bladder permeability could represent an etiologic factor in both interstitial cystitis-bladder pain syndrome and irritable bowel syndrome. We used an animal model of catheterized ovariectomized female rats instilled intravesically with 1 mg/mL PS for 10 minutes that after 24 hours were treated with 1.2 mg/mL lubricin or with vehicle alone. After 24 hours the bladder and colon were removed and permeability assessed electrophysiologically with the Ussing chamber to measure the transepithelial electrical resistance. A second set of rats was treated identically, except permeability was assessed on day 3 and on day 5 using contrast-enhanced magnetic resonance imaging with gadolinium diethylenetriamine penta-acetic acid instilled into the bladder. Intravesical lubricin reversed bladder permeability induced by PS and prevented the concomitant increase in permeability induced in the bowel (organ crosstalk). The protective effect was confirmed with magnetic resonance imaging, and because individual rats could be followed over time, the impermeability of the bladder restored by rhPRG4 remained for 5 days. These data indicate that instillation of rhPRG4 into a permeable bladder can restore its normally impermeable state, and that the effect lasts for 5 days and also prevents bowel symptoms often comorbid with interstitial cystitis-bladder pain syndrome.